Short answer: Insulin aspart has a half-life of about 81 minutes (NovoLog); about 1.1 hours (Fiasp). Levels peak 40 to 50 minutes (NovoLog); about 63 minutes (Fiasp) after a dose. People vary, so treat these as estimates.
Insulin aspart is a rapid-acting (mealtime) insulin: a lab-made insulin with one amino acid changed so it is absorbed faster than regular human insulin. It is sold as NovoLog and as Fiasp, a faster-acting formula, and as the premixed NovoLog Mix 70/30.
Also known as: NovoLog, Fiasp.
NovoLog is U-100 (100 units/mL) in a 10 mL vial, 3 mL PenFill cartridges, a 3 mL FlexPen and a 3 mL FlexTouch. Fiasp is U-100 in a 10 mL vial, a 3 mL FlexTouch pen, 3 mL PenFill cartridges and 1.6 mL PumpCart cartridges for pumps.
The labels approve insulin aspart to improve blood sugar control in adults and children with diabetes. Label timing: NovoLog is injected under the skin within 5 to 10 minutes before a meal; Fiasp at the start of a meal or within 20 minutes after starting it. Both are usually used with an intermediate- or long-acting insulin, and the dose is set for each person. Both can be used in an insulin pump or given into a vein under medical supervision. Fiasp is not mixed with any other insulin. NovoLog has no missed-dose rule; the Fiasp label says that after a forgotten mealtime dose, blood sugar is checked to decide whether a dose is needed.
Neither label has a boxed warning. Low blood sugar is the most common side effect of every insulin, and severe lows can cause seizures or death. The labels also warn: never share a pen, cartridge or syringe, even with a new needle; changes in insulin type, maker, strength or injection site are made under medical supervision with more glucose checks; insulin mix-ups have happened, so the label is checked before each injection; insulin can lower potassium; and heart failure can worsen when insulin is used with a thiazolidinedione such as pioglitazone. Severe low blood sugar affected 17% of adults with type 1 diabetes over 24 weeks in the NovoLog trial; in the Fiasp adult type 1 trial, nasopharyngitis affected 20.2% to 23.9%. See side effects of NovoLog and Fiasp; dosing schedules for NovoLog and Fiasp; missed doses for NovoLog and Fiasp; storage for NovoLog, Fiasp and NovoLog Mix 70/30. Comparisons: Fiasp vs NovoLog, Fiasp vs Lyumjev, Humalog vs NovoLog, NovoLog vs Apidra, Novolin R vs NovoLog and Humalog Mix vs NovoLog Mix. What 70/30 means: premixed insulin.
The NovoLog label gives a median time to peak of 40 to 50 minutes (80 to 120 minutes for regular human insulin) and an average apparent half-life of 81 minutes after an injection under the skin in healthy men. Its strongest glucose-lowering effect came 1 to 3 hours after a dose, and the effect lasted 3 to 5 hours. The Fiasp label says insulin aspart appeared in the blood about 2.5 minutes after a dose, peaked at about 63 minutes, and had an apparent half-life of about 1.1 hours; its effect returned to baseline after about 5 to 7 hours, depending on dose.
Numbers shown are taken from the source above. Half-life varies from person to person.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator